ReviewRenal failure2025
Sustained low-efficiency dialysis-an old method but possibly a new solution for environmental nephrology.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Slow low-efficiency dialysis (SLED) is viewed historically a 'hybrid' technique of kidney replacement therapy, representing a transition between intermittent and continuous kidney replacement therapy. It can be performed with a mobile single-pass batch dialysis system or multifunctional hemodialysis machines, using reduced dialysate flow and an extended procedure duration. We summarized the technical aspects, as well as the practical advantages of SLED. Moreover, we present our experience of using SLED in selected difficult clinical conditions, such as intraoperative renal replacement therapy during liver transplantation, in sepsis, and in heart failure patients with recalcitrant volume overload. In this paper, we aimed to describe the unique advantages of SLED in terms of efficacy, safety, and, more importantly, sustainability in kidney care in the intensive care units.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.